Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03538587|
Recruitment Status : Completed
First Posted : May 29, 2018
Last Update Posted : September 15, 2022
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
People cope with cancer in different ways. Mindfulness means focusing on the present moment with an open mind. Researchers want to see if this can help children and young adults with a high-grade high-risk cancer with poor prognosis.
To learn if mindfulness is feasible and acceptable for children and young people with high-grade high-risk cancer with poor prognosis and their caregivers.
Children ages 5 24 with a high-grade or high-risk cancer, with a caregiver who agrees to do the study
Must have internet access (participants may borrow an iPod for the study)
Must speak English
All participants will complete questionnaires. These will be about feelings, physical well-being, quality of life, and mindfulness.
Researchers will review children s medical records.
Participants will be randomly put in the mindfulness group or the standard care group.
Participants in the standard care group will:
Get general recommendations for coping with cancer
Have check-in sessions 1 and 3 weeks after starting. These will last about 10 minutes each.
After participants finish the standard care group, they may be able to enroll in the mindfulness group.
Participants in the mindfulness group will:
Attend an in-person mindfulness training session. The child participant will meet with one research team member for 90 minutes while the parent participant meets with another. Then they will come together for a half hour.
Practice mindfulness exercises at least 4 days a week for 8 weeks.
Be asked to respond to weekly emails or texts asking about their mindfulness practice
Get a mindfulness kit with things to help them do their mindfulness activities at home.
Have a 30-minute check-in with their coach 1 and 3 weeks after starting. This can be in person or by video chat.
All participants (from both groups) will be asked to answer follow-up questions about 8 and 16 weeks after starting the study. Participants will be paid $20 for each set of questionnaires they complete to thank them for their time.
|Condition or disease||Intervention/treatment||Phase|
|Glioblastomas Sarcoma Astrocytoma Brain Cancer Leukemia||Behavioral: Enhanced Mindfulness Intervention Behavioral: Psychoeducation||Not Applicable|
- Children and young adults diagnosed with a high-grade or high-risk cancer (e.g., diffuse intrinsic pontine glioma, glioblastoma multiforme, relapsed-refractory leukemia, refractory metastatic sarcomas) face a poor prognosis given limited curative options.
- Recent research has indicated that this population of patients and their parents experience elevated stress and poorer health-related quality of life (HRQL) relative to normative samples.
- Recently published psychosocial standards of care in pediatric oncology strongly recommend that children diagnosed with cancer and their caregivers receive early and continued assessment of their wellbeing and have access to interventions to optimize functioning and HRQL. In addition, there is increasing recognition of the importance of palliative interventions early in the disease trajectory.
- Despite this recommendation, minimal research has examined supportive care interventions for this population early in the disease trajectory.
- Mindfulness-based interventions (MBIs) have empirical support for their feasibility and efficacy in alleviating emotional distress and physical symptoms in children and adults with chronic health conditions, including terminally-ill patients and their caregivers.
-To assess the feasibility of an enhanced mindfulness intervention (EMI) in children and young adults (ages 5-24 years) with a high-grade or high-risk cancer with poor prognosis and one of their primary caregivers.
- Children and young adults ages 5-24 years and a parent or adult primary caregiver
- Diagnosis of a high-grade or high-risk cancer with poor prognosis
- English speaking
- Must have access to a mobile device or computer with internet.
- Potential participants will be excluded if there is evidence of pre-morbid severe cognitive or psychiatric disability in parent or child that would impair their capacity for participation, or if there is evidence of clinical disease progression at the time of referral to this study, such that it would prevent the child from engaging in the intervention.
- This is a pilot randomized controlled trial that will compare feasibility and preliminary efficacy of an 8-week EMI group (n=10 dyads) compared to a psychoeducation control group (n=10 dyads).
- All participants will complete measures of feasibility (primary outcome) and exploratory outcomes at baseline and following the 8-week intervention. Exploratory measures will include emotional (e.g., depression, anxiety) and physical (e.g., pain, fatigue) wellbeing, as well as baseline mindfulness/self-compassion.
- The 8-week EMI will consist of one initial in-person session with the child and parent, a series of at-home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer.
- The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial|
|Actual Study Start Date :||January 29, 2019|
|Actual Primary Completion Date :||September 13, 2022|
|Actual Study Completion Date :||September 13, 2022|
Active Comparator: 1/EMI Group
Participate in an in-person session followed by a series of at-home assignments, and two booster sessions.
Behavioral: Enhanced Mindfulness Intervention
The 8-week EMI will consist of one initial in-person session with the participant and parent, a series of at home assignments, and two "booster" sessions. The psychoeducation group will be given educational material about coping with cancer.
Active Comparator: 2/Control Group
Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline.
- Feasibility [ Time Frame: 8 weeks from study entry ]Descriptive and summary statistics will be used to report parent and child ratings of intervention completion, as well as satisfaction with the intervention via responses on a feasibility questionnaire.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||5 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- INCLUSION CRITERIA FOR CHILDREN:
- Patients diagnosed with a high-risk/high-grade cancer (e.g., high-grade brain tumors, relapsed/refractory acute lymphoblastic leukemia, acute myeloid leukemia, high-grade sarcoma) characterized by poor prognosis (e.g., estimated 5-year survival rate <30% based on scientific consensus in the literature, where available, or by expert physician report), as confirmed by medical record review.
- Patients with active disease
- Age greater than or equal to 5 years and less than or equal to 24 years of age
- Must be able to speak and understand English.
- Must have a parent or adult primary caregiver willing to participate in the study.
- Ability of subject or parent/guardian to understand and the willing to sign a written informed consent document.
- Must have access to a computer/mobile device and the internet.
EXCLUSION CRITERIA FOR PATIENTS:
- Patients will be excluded if there is evidence of pre-morbid severe cognitive or psychiatric disability that would impair their capacity for participation or completion of evaluations in the judgment of the investigators.
- Evidence of disease progression at the time of referral to this study to the extent that it would impede participation or completion of evaluations as determined by the medical advisory investigator in conjuction with the study PI/adjunct PI.
- Patients with treatment-related sequelae so severe that they would be unable to complete the study-related evaluations or intervention (e.g., treatment toxicity) as determined by the medical advisory investigator in conjuction with the study PI/adjunct PI.
INCLUSION CRITERIA FOR PARENT OR ADULT PRIMARY CAREGIVER:
- Must be a parent or primary caregiver of a child (age 5 to 24 years of age) who has been diagnosed with a high-grade/high risk tumor that carries poor prognosis (as defined above); and must live in the same household as the patient for a majority of the time.
- Must have a child willing to participate in the study
- Must be able to speak and understand English.
- Ability of subject to understand and the willing to sign a written informed consent document.
- Must have access to a computer/mobile device and the internet.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03538587
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Staci M Peron, Ph.D.||National Cancer Institute (NCI)|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
|First Posted:||May 29, 2018 Key Record Dates|
|Last Update Posted:||September 15, 2022|
|Last Verified:||September 13, 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||.All IPD recorded in the medical record will be shared with intramural investigators upon request.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
|Time Frame:||Clinical data available during the study and indefinitely.|
|Access Criteria:||Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Refractory Metastic Sarcoma
Diffuse Intrinsic Pontine Glioma DIPG
Quality of Life
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Central Nervous System Diseases
Nervous System Diseases